Objective: In December 2019, a new coronavirus is spreading in China at a faster pace. This paper focuses on the regional differences in mortality rate to provide useful references and suggestions for the prevention and control of 2019-nCoV pneumonia in other regions of the world. Material/Methods: Data resource: All date of cases In Yunnan Province was confirmed by the author. Another data came from the authority announcement which is update by hours. All data are beginning announced after January 29.2020 when WHO announces a new outbreak of coronavirus pneumonia as a public health emergency of international concern (PHEIC) at 4 a.m. on January 31.2020. Mortality Rate: All statistical analyses were made using SPSS13.0 for Windows software (SPSS Inc., Chicago). The data indicated are expressed as mean ± standard deviation. The t-test was used to compare the variables between groups. P-value greater than 0.005 was considered as statistically significant, Crude mortality (‰)=number of dead individuals per unit time/number of sicknesses per unit time × 1000 ‰. Results: As of 11:34 on April 16, 2020, In China, there were 83,797 confirmed cases, 63 suspected cases, Severe cases 95, 3,352 cases died, 78,504 cases were cured and 713,523 cases were released from medical observation. Hubei has reported 67,803 cases of new crown pneumonia (including 146 cases of clinical diagnosis), among which 50,008 cases (including 146 cases of clinical diagnosis) in Wuhan city, The oversea case is 1,426,071, and only 133818 case died. Crude mortality of Hubei is 47.52 (‰). The crude mortality rate of Hubei Province is significantly different from other provinces (P-value greater than 0.005). Conclusions: Recent COVID-19 case data show that there are not only more cases but also higher mortality rates in the source areas. It revealed a situation that the lack of medical resources and treatment capacity. Effective epidemic prevention can prevent such a situation. Paying attention to the treatment of light patients is conducive to their conversion into severe, and then reduce the mortality. Low mortality rate of Novel Coronavirus Pneumonia (COVID-19) outside of the main epidemic area Wuhan shows active medical treatment is the key to reduce mortality.
Published in | American Journal of Health Research (Volume 8, Issue 3) |
DOI | 10.11648/j.ajhr.20200803.12 |
Page(s) | 26-31 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2020. Published by Science Publishing Group |
Novel Coronavirus, 2019-nCoV, COVID-19, Mortality
[1] | Wan Yushun., Shang Jian., Graham Rachel., Baric Ralph S., Li Fang.(2020). Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J. Virol., 94 (7), undefined. doi: 10.1128/JVI.00127-20. |
[2] | Ji Wei., Wang Wei., Zhao Xiaofang., Zai Junjie., Li Xingguang.(2020). Cross-species transmission of the newly identified coronavirus 2019-nCoV. J. Med. Virol., 92 (4), 433-440. doi: 10.1002/jmv.25682. |
[3] | Guarner Jeannette. (2020). Three Emerging Coronaviruses in Two Decades. Am. J. Clin. Pathol., 153 (4), 420-421. doi: 10.1093/ajcp/aqaa029. |
[4] | Al-Tawfiq J A., Rodriguez-Morales A J.(2020). Super-spreading events and contribution to transmission of MERS, SARS, and COVID-19. J. Hosp. Infect., undefined (undefined), undefined. doi: 10.1016/j.jhin.2020.04.002. |
[5] | Wu Joseph T., Leung Kathy., Bushman Mary., Kishore Nishant., Niehus Rene., de Salazar Pablo M., Cowling Benjamin J., Lipsitch Marc., Leung Gabriel M.(2020). Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat. Med., 26 (4), 506-510. doi: 10.1038/s41591-020-0822-7. |
[6] | Mahase Elisabeth.(2020). Coronavirus covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate. BMJ, 368 (undefined), m641. doi: 10.1136/bmj.m641. |
[7] | Yan Yuxin., Shin Woo In., Pang Yoong Xin., Meng Yang., Lai Jianchen., You Chong., Zhao Haitao., Lester Edward., Wu Tao., Pang Cheng Heng.(2020). The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment. Int J Environ Res Public Health, 17 (7), undefined. doi: 10.3390/ijerph17072323. |
[8] | Singhal Tanu.(2020). A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr, 87 (4), 281-286. doi: 10.1007/s12098-020-03263-6. |
[9] | Chu Hin., Chan Jasper Fuk-Woo., Wang Yixin., Yuen Terrence Tsz-Tai., Chai Yue., Hou Yuxin., Shuai Huiping., Yang Dong., Hu Binjie., Huang Xiner., Zhang Xi., Cai Jian-Piao., Zhou Jie., Yuan Shuofeng., Kok Kin-Hang., To Kelvin Kai-Wang., Chan Ivy Hau-Yee., Zhang Anna Jinxia., Sit Ko-Yung., Au Wing-Kuk., Yuen Kwok-Yung. (2020). Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19. Clin. Infect. Dis., undefined (undefined), undefined. doi: 10.1093/cid/ciaa410. |
[10] | Chan Jasper Fuk-Woo., Yuan Shuofeng., Kok Kin-Hang., To Kelvin Kai-Wang., Chu Hin., Yang Jin., Xing Fanfan., Liu Jieling., Yip Cyril Chik-Yan., Poon Rosana Wing-Shan., Tsoi Hoi-Wah., Lo Simon Kam-Fai., Chan Kwok-Hung., Poon Vincent Kwok-Man., Chan Wan-Mui., Ip Jonathan Daniel., Cai Jian-Piao., Cheng Vincent Chi-Chung., Chen Honglin., Hui Christopher Kim-Ming., Yuen Kwok-Yung. (2020). A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet, 395 (10223), 514-523. doi: 10.1016/S0140-6736(20)30154-9. |
[11] | Leung Char.(2020). Risk factors for predicting mortality in elderly patients with COVID-19: A review of clinical data in China. Mech. Ageing Dev., 188 (undefined), 111255. doi: 10.1016/j.mad.2020.111255. |
[12] | Xu Guogang., Yang Yongshi., Du Yingzhen., Peng Fujun., Hu Peng., Wang Runsheng., Yin Ming., Li Tianzhi., Tu Lei., Sun Jinlyu., Jiang Taijiao., Chang Christopher.(2020). Clinical Pathway for Early Diagnosis of COVID-19: Updates from Experience to Evidence-Based Practice. Clin Rev Allergy Immunol, undefined (undefined), undefined. doi: 10.1007/s12016-020-08792-8. |
[13] | Su Shuo., Wong Gary., Shi Weifeng., Liu Jun., Lai Alexander C K., Zhou Jiyong., Liu Wenjun., Bi Yuhai., Gao George F. (2016). Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses. Trends Microbiol., 24 (6), 490-502. doi: 10.1016/j.tim.2016.03.003. |
[14] | Chen Nanshan., Zhou Min., Dong Xuan., Qu Jieming., Gong Fengyun., Han Yang., Qiu Yang., Wang Jingli., Liu Ying., Wei Yuan., Xia Jia'an., Yu Ting., Zhang Xinxin., Zhang Li. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 395 (10223), 507-513. doi: 10.1016/S0140-6736(20)30211-7. |
[15] | Huang Chaolin., Wang Yeming., Li Xingwang., Ren Lili., Zhao Jianping., Hu Yi., Zhang Li., Fan Guohui., Xu Jiuyang., Gu Xiaoying., Cheng Zhenshun., Yu Ting., Xia Jiaan., Wei Yuan., Wu Wenjuan., Xie Xuelei., Yin Wen., Li Hui., Liu Min., Xiao Yan., Gao Hong., Guo Li., Xie Jungang., Wang Guangfa., Jiang Rongmeng., Gao Zhancheng., Jin Qi., Wang Jianwei., Cao Bin. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395 (10223), 497-506. doi: 10.1016/S0140-6736(20)30183-5. |
[16] | Dramé Moustapha., Teguo Maturin Tabue., Proye Emeline., Hequet Fanny., Hentzien Maxime., Kanagaratnam Lukshe., Godaert Lidvine.(2020). Should RT-PCR be considered a gold standard in the diagnosis of Covid-19? J. Med. Virol., undefined (undefined), undefined. doi: 10.1002/jmv.25996. |
[17] | Zhang Chi., Chen Cai., Shen Wei., Tang Feng., Lei Hao., Xie Yu., Cao Zicheng., Tang Kang., Bai Junbo., Xiao Lehan., Xu Yutian., Song Yanxin., Chen Jiwei., Guo Zhihui., Guo Yichen., Wang Xiao., Xu Modi., Zou Huachun., Shu Yuelong., Du Xiangjun.(2020). Impact of population movement on the spread of 2019-nCoV in China. Emerg Microbes Infect, undefined (undefined), 1-28. doi: 10.1080/22221751.2020.1760143. |
[18] | Wang Yun-Yun., Jin Ying-Hui., Ren Xue-Qun., Li Yi-Rong., Zhang Xiao-Chun., Zeng Xian-Tao., Wang Xing-Huan., Zhongnan Hospital of Wuhan University Novel Coronavirus Management and Research Team. (2020). Updating the diagnostic criteria of COVID-19 "suspected case" and "confirmed case" is necessary. Mil Med Res, 7 (1), 17. doi: 10.1186/s40779-020-00245-9. |
APA Style
Li Juan Feng, Li Guo, Qing Yang, Qing Mei Yang, Yue Yi Zhang, et al. (2020). Low Mortality Rate of Novel Coronavirus Pneumonia (COVID-19) - Outside of the Main Epidemic Area Wuhan. American Journal of Health Research, 8(3), 26-31. https://doi.org/10.11648/j.ajhr.20200803.12
ACS Style
Li Juan Feng; Li Guo; Qing Yang; Qing Mei Yang; Yue Yi Zhang, et al. Low Mortality Rate of Novel Coronavirus Pneumonia (COVID-19) - Outside of the Main Epidemic Area Wuhan. Am. J. Health Res. 2020, 8(3), 26-31. doi: 10.11648/j.ajhr.20200803.12
AMA Style
Li Juan Feng, Li Guo, Qing Yang, Qing Mei Yang, Yue Yi Zhang, et al. Low Mortality Rate of Novel Coronavirus Pneumonia (COVID-19) - Outside of the Main Epidemic Area Wuhan. Am J Health Res. 2020;8(3):26-31. doi: 10.11648/j.ajhr.20200803.12
@article{10.11648/j.ajhr.20200803.12, author = {Li Juan Feng and Li Guo and Qing Yang and Qing Mei Yang and Yue Yi Zhang and Fei Fei Yang}, title = {Low Mortality Rate of Novel Coronavirus Pneumonia (COVID-19) - Outside of the Main Epidemic Area Wuhan}, journal = {American Journal of Health Research}, volume = {8}, number = {3}, pages = {26-31}, doi = {10.11648/j.ajhr.20200803.12}, url = {https://doi.org/10.11648/j.ajhr.20200803.12}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajhr.20200803.12}, abstract = {Objective: In December 2019, a new coronavirus is spreading in China at a faster pace. This paper focuses on the regional differences in mortality rate to provide useful references and suggestions for the prevention and control of 2019-nCoV pneumonia in other regions of the world. Material/Methods: Data resource: All date of cases In Yunnan Province was confirmed by the author. Another data came from the authority announcement which is update by hours. All data are beginning announced after January 29.2020 when WHO announces a new outbreak of coronavirus pneumonia as a public health emergency of international concern (PHEIC) at 4 a.m. on January 31.2020. Mortality Rate: All statistical analyses were made using SPSS13.0 for Windows software (SPSS Inc., Chicago). The data indicated are expressed as mean ± standard deviation. The t-test was used to compare the variables between groups. P-value greater than 0.005 was considered as statistically significant, Crude mortality (‰)=number of dead individuals per unit time/number of sicknesses per unit time × 1000 ‰. Results: As of 11:34 on April 16, 2020, In China, there were 83,797 confirmed cases, 63 suspected cases, Severe cases 95, 3,352 cases died, 78,504 cases were cured and 713,523 cases were released from medical observation. Hubei has reported 67,803 cases of new crown pneumonia (including 146 cases of clinical diagnosis), among which 50,008 cases (including 146 cases of clinical diagnosis) in Wuhan city, The oversea case is 1,426,071, and only 133818 case died. Crude mortality of Hubei is 47.52 (‰). The crude mortality rate of Hubei Province is significantly different from other provinces (P-value greater than 0.005). Conclusions: Recent COVID-19 case data show that there are not only more cases but also higher mortality rates in the source areas. It revealed a situation that the lack of medical resources and treatment capacity. Effective epidemic prevention can prevent such a situation. Paying attention to the treatment of light patients is conducive to their conversion into severe, and then reduce the mortality. Low mortality rate of Novel Coronavirus Pneumonia (COVID-19) outside of the main epidemic area Wuhan shows active medical treatment is the key to reduce mortality.}, year = {2020} }
TY - JOUR T1 - Low Mortality Rate of Novel Coronavirus Pneumonia (COVID-19) - Outside of the Main Epidemic Area Wuhan AU - Li Juan Feng AU - Li Guo AU - Qing Yang AU - Qing Mei Yang AU - Yue Yi Zhang AU - Fei Fei Yang Y1 - 2020/06/04 PY - 2020 N1 - https://doi.org/10.11648/j.ajhr.20200803.12 DO - 10.11648/j.ajhr.20200803.12 T2 - American Journal of Health Research JF - American Journal of Health Research JO - American Journal of Health Research SP - 26 EP - 31 PB - Science Publishing Group SN - 2330-8796 UR - https://doi.org/10.11648/j.ajhr.20200803.12 AB - Objective: In December 2019, a new coronavirus is spreading in China at a faster pace. This paper focuses on the regional differences in mortality rate to provide useful references and suggestions for the prevention and control of 2019-nCoV pneumonia in other regions of the world. Material/Methods: Data resource: All date of cases In Yunnan Province was confirmed by the author. Another data came from the authority announcement which is update by hours. All data are beginning announced after January 29.2020 when WHO announces a new outbreak of coronavirus pneumonia as a public health emergency of international concern (PHEIC) at 4 a.m. on January 31.2020. Mortality Rate: All statistical analyses were made using SPSS13.0 for Windows software (SPSS Inc., Chicago). The data indicated are expressed as mean ± standard deviation. The t-test was used to compare the variables between groups. P-value greater than 0.005 was considered as statistically significant, Crude mortality (‰)=number of dead individuals per unit time/number of sicknesses per unit time × 1000 ‰. Results: As of 11:34 on April 16, 2020, In China, there were 83,797 confirmed cases, 63 suspected cases, Severe cases 95, 3,352 cases died, 78,504 cases were cured and 713,523 cases were released from medical observation. Hubei has reported 67,803 cases of new crown pneumonia (including 146 cases of clinical diagnosis), among which 50,008 cases (including 146 cases of clinical diagnosis) in Wuhan city, The oversea case is 1,426,071, and only 133818 case died. Crude mortality of Hubei is 47.52 (‰). The crude mortality rate of Hubei Province is significantly different from other provinces (P-value greater than 0.005). Conclusions: Recent COVID-19 case data show that there are not only more cases but also higher mortality rates in the source areas. It revealed a situation that the lack of medical resources and treatment capacity. Effective epidemic prevention can prevent such a situation. Paying attention to the treatment of light patients is conducive to their conversion into severe, and then reduce the mortality. Low mortality rate of Novel Coronavirus Pneumonia (COVID-19) outside of the main epidemic area Wuhan shows active medical treatment is the key to reduce mortality. VL - 8 IS - 3 ER -